NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT00003635 2013-07-18
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002970 2013-07-02
506U78 in Treating Patients With Refractory Hematologic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003545 2013-02-05
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005950 2013-01-23
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00005982 2013-01-23
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00005080 2013-01-16
506U78 in Treating Patients With Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed